Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02803203 · ClinicalTrials.gov registry record · Phase 1
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT02803203: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02803203 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02803203, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of combining the drugs osimertinib and bevacizumab at different dose levels. The investigators want to find out what effects, good and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study will try to find the best dose of osimertinib and bevacizumab given together that does not cause significant side effects. Once the investigators determine that combining osimertinib and bevacizumab is safe, they want to see if the combination is effective in treating lung cancers with the EGFR mutation.
Interventions
- DRUG Bevacizumab
- DRUG osimertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02803203
The ClinicalTrials.gov registry entry for NCT02803203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02803203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02803203 about?
NCT02803203 is a clinical study titled "Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers". The purpose of this study is to test the safety of combining the drugs osimertinib and bevacizumab at different dose levels. The investigators want to find out what effects, good and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study will try to find the best d...
What is the current status of trial NCT02803203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2016-06-29. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT02803203?
The interventions under investigation include: Bevacizumab (DRUG), osimertinib (DRUG).
Who is sponsoring clinical trial NCT02803203?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.